<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753103</url>
  </required_header>
  <id_info>
    <org_study_id>RRK2031</org_study_id>
    <nct_id>NCT00753103</nct_id>
  </id_info>
  <brief_title>Anti-Cytokine Therapy for Vasculitis</brief_title>
  <acronym>ACTIVE</acronym>
  <official_title>Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Birmingham NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Infliximab (monoclonal anti-tumour necrosis
      factor alpha antibodies) are safe and effective in the treatment of anti-neutrophil cytoplasm
      antibody (ANCA) associated vasculitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis is a life-threatening
      systemic inflammatory autoimmune disease. Current treatment regimes using corticosteroids and
      cyclophosphamide have improved patient survival but are associated with treatment associated
      morbidity and mortality. Tumour necrosis factor alpha (TNF) is a proinflammatory cytokine
      which has been implicated in the pathogenesis of ANCA vasculitis. Anti-TNF therapies have
      been used successfully in the management of other inflammatory autoimmune diseases. This
      phase II cohort study has been designed to investigate the safety and efficacy of anti-TNF
      monoclonal antibody (Infliximab) therapy for patients with ANCA associated vasculitis when
      used in addition to standard immunosuppressive therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical remission (Birmingham Vasculitis Activity Score 0 or 1)</measure>
    <time_frame>0, 6, 10, 14, 26, 39 and 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Weeks 2, 6, 10, 14, 26, 39, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasculitis Damage Index Score</measure>
    <time_frame>Weeks 0, 14, 26, 39, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Weeks 0, 2, 6, 10, 14, 26, 39, 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Renal Limited Vasculitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with active vasculitis who receive infliximab in addition to standard immunosuppressive therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with active ANCA associated vasculitis who receive standard immunosuppression but no infliximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Daily oral 1mg/kg tapered over 12 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma exchange</intervention_name>
    <description>Additional therapy for patients with severe vasculitis (creatinine &gt; 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>500 mg intravenous infusion daily for three days at lead physicians discretion.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either newly diagnosed or relapsed ANCA associated vasculitis (Wegener's
             granulomatosis, microscopic polyangiitis, renal limited vasculitis)

        Exclusion Criteria:

          -  Active infection

          -  Malignancy

          -  Pregnancy

          -  Diagnosis of Churg-Strauss syndrome or anti-glomerular basement membrane antibody
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorraine Harper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>September 15, 2008</last_update_submitted>
  <last_update_submitted_qc>September 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Lorraine Harper</name_title>
    <organization>University Hospitals Birmingham NHS Foundation Trust/University of Birmingham</organization>
  </responsible_party>
  <keyword>Infliximab</keyword>
  <keyword>Vasculitis</keyword>
  <keyword>antitnf monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

